The findings above showed the remarkable effects of TIM-3 and PD-1 blockades in preventing HPD in mice under anti-PD-1 monotherapy, and we further evaluated the in vivo preclinical applicative value of TIM-3 and PD-1 co-blockades in treating ovarian tumor-bearing mice. Here, PDCD1 is linked to ovarian neoplasm.